Crystallographic analysis of the charge-transfer complex indicated that a Mo-nitrogen-carbon bond was formed between molybdenum of XOR and the nitrile group of trihydroxy-FYX-051. FYX-051
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Introduction:
Mammalian xanthine oxidoreductase (XOR) catalyzes the last two steps in the purine degradation pathway prior to formation of uric acid, i.e., hydroxylation of hypoxanthine to xanthine and of xanthine to uric acid. The enzyme is a homo-dimer with molecular mass of 290 kDa; each subunit contains one molybdenum cofactor, two [2Fe-2S] centers, and one FAD center. The oxidative hydroxylation of purine substrates takes place at the molybdenum center, and reducing equivalents thus introduced are transferred via the two [2Fe-2S] centers to the FAD center, where reduction of the physiological electron acceptor, NAD + or O 2 , occurs. XOR is a good target of drugs to treat gout and hyperuricemia. Allopurinol (Fig. 1C) , a hypoxanthine isomer, was introduced by Elion et al. (1963) as an inhibitor of XOR more than 40 years ago and has been extensively prescribed for gout and hyperuricemia patients since then. Massey et al. (1970) reported that the hydroxylated metabolite produced by XOR, oxipurinol, binds tightly to the reduced Mo(IV) of the enzyme. Crystal structure analysis of the oxipurinol-bound form of the reduced bovine XOR indicated that the water-exchangeable -OH ligand of the Mo(IV) atom was replaced by N2 of oxipurinol (Okamoto et al., 2008) (Fig. 1D) . It is known, however, that oxipurinol dissociates with t 1/2 = 300 min at 25 °C from the molybdenum owing to spontaneous reoxidation of Mo(IV) to Mo(VI) (Massey et al., 1970) .
Therefore, despite the excellent pharmacokinetics properties of allopurinol, administration at a relatively high dose is normally required and it can, though rarely, cause serious adverse effects such as fulminant hepatitis, renal failure or Stevens-Johnson syndrome (Arellano and Sacristan, 1993) .
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Many researchers have attempted to develop new inhibitors without these drawbacks. TEI-6720
(febuxostat) was recently developed as a non-purine selective inhibitor of XOR, showing a more potent and longer-lasting urate-lowering effect than allopurinol in rodents (Osada et al., 1993) and chimpanzees (Komoriya et al., 1993) . Clinical efficacy and tolerance to febuxostat have been confirmed (Becker et al., 2005) , and the drug has been approved both in the United States and
European Union for the treatment of gout.
FYX-051 ( Fig. 1A ) has recently been developed as another new type of XOR inhibitor. It not only forms a covalent linkage to molybdenum via oxygen in the hydroxylation reaction intermediate, but
also interacts with amino acid residues of the solvent channel, like the structure-based inhibitor TEI-6720 Okamoto et al., 2003) (Fig. 1B) . In addition, because FYX-051 has high bioavailability and safety in animals (Shimo et al., 2005) , it is a candidate drug for hyperuricemia and gout. Here we investigated the inhibitor-enzyme interaction and the in vivo hypouricemic effect of FYX-051 in order to clarify the biochemical and pharmacological properties of this new inhibitor and its hydroxylated derivatives. We also report the prominent spectral perturbation of a trihydroxylated metabolite of the inhibitor, together with the results of crystallographic analysis of the enzyme-inhibitor complex.
This article has not been copyedited and formatted. The final version may differ from this version. 2-Hydroxy-FYX-051, allopurinol and oxipurinol were dissolved in 0.1 N NaOH. For in vivo study, FYX-051 and allopurinol were suspended in 0.5% (w/v) methylcellulose solution at a constant volume of 5 ml/kg body weight.
Protein purification. Bovine milk xanthine oxidase (XO) was purified using the method of Ball (1939) . The active form of the enzyme was further separated from the inactive desulfo-form by folate affinity chromatography according to the method of Nishino et al. (1981) . The activity to flavin ratio (AFR) values of the prepared enzyme, which were obtained by dividing the absorbance change per minute at 295 nm under standard assay conditions by the enzyme absorbance at 450 nm (Bray, 1975) , were more than 180 (fully active enzyme has a value of 210) (Massey et al., 1970) . The xanthine dehydrogenase (XDH) form of the enzyme was prepared according to the method of Eger et al. (2000) .
The concentration of the enzyme was determined spectrophotometrically using a molar extinction of 37,800 M -1 cm -1 at 450 nm (Massey et al., 1969 and fully active XO (13 μ M) were mixed anaerobically in 1 ml of solution containing 20 mM pyrophosphate buffer (pH 8.5), 40 mM Tris-HCl buffer (pH 7.8), and 0.2 mM EDTA. For the preparation of the complex of the enzyme with trihydroxy-FYX-051, equivalent amounts of purified trihydroxy-FYX-051 (11 μ M) and fully active XO (11 μ M) in 1 ml of the above buffer was mixed anaerobically, followed by reductive titration with sodium dithionite using a gas-tight titrating syringe.
Spectral changes of both complexes after incubation at room temperature were measured with a spectrophotometer (DU-7400, Beckmann).
This article has not been copyedited and formatted. The final version may differ from this version. Crystallization of XDH-FYX-051 (or metabolite) complex. Crystals of the FYX-051 complex of bovine XDH were obtained by modification of a published method (Eger et al., 2000) . To obtain the metabolite complex, salicylate was removed from enzyme stock solutions by gel filtration, and the sample was then diluted to a protein concentration of about 6 mg/ml. One and a half volumes of FYX-051 was mixed anaerobically with the enzyme, and the absorption spectrum of the mixture was monitored at room temperature until the charge transfer band around 600 nm reached the maximum.
Then the enzyme-inhibitor mixture was transferred to an argon atmosphere, under which all subsequent manipulations were performed. The enzyme-inhibitor mixture was concentrated with a centrifugal filter unit (Microcon YM-100, Millipore) to a protein concentration of about 60 mg/ml, and then 30 mg/ml enzyme solution containing 30% (wt/vol) glycerol and 5 mM DTT was prepared.
Aliquots (10 μ l) of enzyme solution were mixed with 10 μ l of 50 mM potassium phosphate buffer (pH 6.5) containing 8.0-9.5% polyethylene glycol 4,000, 30% glycerol (wt/vol), 0.2 mM EDTA, and 5 mM DTT. The solutions were dropped on siliconized glass plates, and kept in the dark at 22 °C in the argon-filled box. Crystals grew after 5 days; they belonged to the same C2 space group as the original crystals, with almost the same unit cell parameters of a = 168.9 Å, b = 124.7 Å, c = 146.2 Å, and β = 91.0°. The crystals were collected with a nylon loop, shock-frozen, and stored in liquid nitrogen.
Data collection and data refinement. A complete 2.2 Å diffraction data set was collected at the Photon Factory (Tsukuba, Japan), beamline NW12A at λ = 1.000 Å ( , 1994) . Figure 7 was generated with the program Pymol.
Animals. Male Wistar/ST strain rats (7 weeks old; purchased from Japan SLC, Inc., Shizuoka, Japan) were kept in an air-conditioned room with a standard 12-hour light-dark cycle. They were given standard chow and water ad libitum throughout the acclimatization and experimental periods.
Measurement of serum urate in rats treated with inhibitors. FYX-051 or allopurinol was orally administered to rats, and blood was collected under ether anesthesia from the orbital sinus at 0.5, 1, 2, 6, and 12 hours after drug administration. In order to maintain hyperuricemia during the experimental period, potassium oxonate (250 mg/kg, s.c.; uricase inhibitor) was repeatedly injected at 4-hour intervals. The blood was allowed to clot for 1 hour at room temperature and then centrifuged. Serum urate level was measured by the phosphotungstic acid method (Henry, 1957) . ED 50 values of inhibitors were calculated from the extent of decrease compared with the control by using the probit method.
Statistical analysis. The mean and standard deviation of serum urate levels were calculated, and the difference between the control and treated groups was analyzed by using Dunnett's test (at significance levels of 5% and 1%).
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Time-dependent inhibition of XO with inhibitors and the stability of XO-inhibitor complexes.
FYX-051 displayed time-and concentration-dependent inhibition of urate formation under air-saturated conditions ( Fig. 2A) . 2-Hydroxy-FYX-051, generated by primary hydroxylation of FYX-051 by XOR itself, also caused time-and concentration-dependent inhibition, although a relatively large amount of 2-hydroxy-FYX-051 was necessary to achieve potent inhibition (Fig. 2B) due to the lower affinity of 2-hydroxy-FYX-051, as determined from steady-state experiments (see below). We also estimated the stability of the XO-inhibitor complexes by determination of the recovery of enzyme activity (Fig. 3) . The complexes of XO with inhibitors seem to be decomposed, likely due to hydrolysis of the intermediate by water under air-saturated conditions at 25 °C, resulting in gradual recovery of the catalytic activity with a half-life (t 1/2 ) of 20.4
hours for the complex of FYX-051 and 19.4 hours for the complex of 2-hydroxy-FYX-051 ( Fig. 3A and B). was stable for at least 72 hours. LC/MS analysis ( Fig. 5E-F) showed that peaks c and d had molecular weights of 280 and 296, i.e., 32 and 48 mass units larger than FYX-051, respectively. Peaks c and d
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were purified by solid-phase extraction using OASIS HLB cartridges and structure determination of the compound obtained from peak c was performed with NMR spectroscopy. It was found that the second and third hydroxylations occurred sequentially at the 6 position of the pyridinecarbonitrile ring ( Fig. 5E ) and the 6 position of the hydroxypyridine ring (Fig. 5F ), respectively.
Spectral changes of XO on mixing with FYX-051 and trihydroxy-FYX-051. As described previously , immediate spectral changes were observed on mixing XOR with FYX-051 due to formation of a covalent reaction intermediate (Fig. 6A) . However, on prolonged incubation (120 hours after mixing), further spectral changes were observed with the appearance of a larger positive peak at 600 nm and a negative peak at 450 nm. No further changes occurred on incubation for longer than 120 hours. When air was admitted, the negative peak at 450 nm completely disappeared, but the larger positive peak at 590 nm (Δε = 11.9 mM -1 cm -1 ) remained stable for at least 30 min. We also observed the spectral changes of dithionite-reduced XO with trihydroxy-FYX-051
( large positive peak at 590 nm (Δε = 9.7 mM -1 cm -1 ) was obtained after reoxidation of the enzyme by exposure to air, indicating that reduced molybdenum and trihydroxy-FYX-051 form an identical complex with that shown in Fig. 6A .
Crystal structure of XDH-FYX-051-metabolite complex. XOR was incubated with FYX-051 until marked spectral perturbation was observed (120 hours), then the complex was crystallized. The crystals were collected and frozen anaerobically, and the crystal structure was determined at 2.2Å
resolution. In the xanthine-binding site, the metabolite is bound in the solvent channel associated with the xanthine hydroxylation site, and is linked with molybdopterin ( Fig. 7A and B) . Based on our analysis of the metabolites of FYX-051 produced by XO (Fig. 5) , we constructed a model with trihydroxy-FYX-051 as the ligand. Trihydroxy-FYX-051 binds with its nitrile residue close to the molybdenum. From the electron density, covalent linkage of the molybdenum and the pyridine ring via oxygen which is to be incorporated into the hydroxyl residue seems unlikely. It seems more likely that the pyridine ring is connected with molybdenum via the nitrile residue of the compound ( Fig. 7A and B). mixed with the enzyme, the amount of 2-hydroxy-FYX-051 formed did not exceed that of the enzyme.
Conversion of FYX-051 and allopurinol to mono-hydroxylated metabolites by XO.
In contrast, excess allopurinol was mostly converted to oxipurinol, regardless of the amount of the enzyme. A 30-fold molar excess of allopurinol was required for full inactivation of the enzyme.
Hypouricemic effect of FYX-051 in oxonate-induced hyperuricemic rats. Changes in serum urate levels of rats at 1 hour after oral administration of FYX-051 and allopurinol are shown in Fig.   9A . Serum urate levels in oxonate-injected rats were increased to 4 mg/dl or less, and were 
Discussion:
In the time course study of XOR inhibition, we found that FYX-051 displayed time-dependent inhibition to urate formation (Fig. 2) . Okamoto et al. (2004) showed that such time-dependent inhibition is due to formation of a stable reaction intermediate by determination of the crystal structure of FYX-051-XDH complex. This showed that FYX-051 forms a covalent bond to molybdenum via oxygen, i.e., a Mo-O-C2-FYX-051 bond. It seems likely that 2-hydroxy-FYX-051, which also exhibits time-dependent inhibition, would interact similarly with XOR, that is, it would undergo further hydroxylation by the enzyme to form another stable reaction intermediate.
The study of complex stability (Fig. 3) by determination of the recovery of enzyme activity showed that FYX-051 XOR complex (Fig. 1B) decomposed with a half-life of 20.4 hours which was more stable than oxipurinol XOR complex ( Fig. 1D ) with 5 hours (Massey et al., 1970) . Interestingly, the recovery of enzyme activity from the FYX-051 XOR complex gradually slowed down and the full enzyme activity was not recovered for 48 hours, and this is consistent with the indication from the time-dependent inhibition studies that 2-hydroxy-FYX-051 and/or a further hydroxylated form of 2-hydroxy-FYX-051 might also have an inhibitory effect.
Although FYX-051 showed potent, time-dependent inhibition of XOR due to the formation of stable reaction intermediates, as described above, FYX-051 and its derivative also display structure-based non-covalent inhibition, as shown by steady-state kinetic analyses based on initial velocity determination (Fig. 4) (Elion, 1966) . Previous study of the crystal structure revealed that FYX-051 XDH complex has various interactions involving amino acid residues in the substrate channel of the enzyme, in addition to the covalent bond to molybdenum . Accordingly, the potent inhibition of the enzyme by FYX-051 in the initial phase can be ascribed to such structural interactions.
Analysis of the metabolites of FYX-051 produced by XOR showed that 2-hydroxy-FYX-051, monohydroxylated metabolite of FYX-051, was further converted to di-and trihydroxy-FYX-051 during prolonged incubation for up to 72 hours (Fig. 5) . These structures are reasonable in terms of the nature of XOR, which normally hydroxylates the carbon atom adjacent to the nitrogen atom of a heterocycle . Trihydroxy-FYX-051 was stable for at least 72 hours, so that this trihydroxy compound may mainly mediate the inhibition and be responsible for the spectral perturbation of XO (Figs. 3 and 6 ).
On prolonged incubation of FYX-051-XOR complex, further spectral changes were observed with the appearance of a larger positive peak at 590 nm (Fig. 6) , suggesting the formation of a new stable charge-transfer complex between the reduced molybdenum center and a metabolite of FYX-051. This is confirmed by the fact that the identical spectrum of charge-transfer complex was obtained from trihydroxy-FYX-051-XOR complex. The wavelength of maximum absorption (λmax = 590 nm) of these charge-transfer complexes was shifted 50 nm to shorter wavelength than that in the case of 2-hydroxy-FYX-051 (λmax = 640 nm) or the violapterin complex (Davis et al., 1982) or the complexes with oxipurinol and its derivatives (Massey et al., 1970) . Thus, the complex of XDH-trihydroxy-FYX-051 is suggested to be quite different from the complexes of XDH with 2-hydroxy-FYX-051 or pyrazolo pyrimidine derivatives. Crystal structure of FYX-051-XOR complex with marked spectral perturbation reveals that the pyridine ring of trihydroxy-FYX-051 is connected with molybdenum via the nitrile residue of the compound (Fig. 7) . The distance between the molybdenum and C1 carbon atom of the ring is 4.3 Å, which is clearly larger than that of the complex with FYX-051 , and fits well with a linkage via the nitrile group. This finding suggests that trihydroxy-FYX-051 forms a covalently bound complex with the molybdenum that is quite different from the reaction intermediate structure . The 2,6-dihydroxypyridine ring binds at the outermost region of the channel and is not clearly defined.
The crystal structure of the trihydroxy-FYX-051 bound form is basically different from that of the FYX-051 bound form, indicating that a major reason for the spectral change is a direct influence of the different covalent linkages between the inhibitor and the molybdenum cofactor. We suggest that the nitrile group would markedly perturb the electronic environment of the Mo-pterin cofactor.
In previous in vivo study, allopurinol is immediately converted to oxipurinol, which is detected in human plasma and urine at relatively high concentration (Hosoya et al., 1991) , whereas only a little 2-hydroxy-FYX-051 is detected in human urine after administration of FYX-051 (Nakazawa et al., 2006) . In the present study, we investigated in vitro hydroxylation by XO in order to clarify the This article has not been copyedited and formatted. The final version may differ from this version. difference in metabolic behavior between two inhibitors in vivo. These results imply that 2-hydroxy-FYX-051 enzyme complex is so stable (Fig. 3 , t 1/2 = about 20 hours) that only a little 2-hydroxy-FYX-051 can be dissociated from the complex (Fig. 8) . Furthermore, 2-hydroxy-FYX-051
was slightly increased when incubation was continued, and no formation of metabolites with two or three hydroxyl groups was observed until nonreacted FYX-051 was completely consumed (data not shown). It is likely that this reflects the difference in binding affinity between FYX-051 and 2-hydroxy-FYX-051 for the enzyme. It is likely that the conversion of allopurinol to oxipurinol continues until oxipurinol-enzyme complex is fully formed, because allopurinol is a good substrate for XOR. This oxipurinol, which is deposited in the kidney during renal excretion, sometimes causes severe adverse effects in patients with renal insufficiency (Hande et al., 1984) . In the case of FYX-051, such an adverse effect would not be expected, since 2-hydroxy-FYX-051 does not easily accumulate, and is not renally excreted.
A previous study showed that repeated allopurinol dosing (30 mg/kg p.o. once daily for 28 days) in normal rats caused severe nephrotoxicity (Horiuchi et al., 1999) . On the other hand, we previously demonstrated that nephropathy in rats occurring after FYX-051 dosing (1 mg/kg p.o. once daily for 28 days) was a secondary change caused by xanthine crystals being deposited in the kidney due to the potent inhibition of XOR (Shimo et al., 2005) . Accordingly, it is likely that the potent and long-lasting hypouricemic effects of FYX-051 (Fig. 9) arise from its high affinity for and stable binding to the enzyme.
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In conclusion, we have studied in detail how FYX-051 interacts with bovine milk XOR. It was found that 2-hydroxy-FYX-051 XOR complex formed is more stable than oxipurinol XOR complex, although FYX-051 as well as allopurinol forms a covalent linkage to molybdenum and exhibits time-dependent inhibition of the enzyme. FYX-051 also displayed a potent, non-covalent inhibition of XOR with a lower K i value of 5.7×10 -9 M than allopurinol. Moreover, we found that XOR hydroxylates three carbons of FYX-051 and finally generates a trihydroxylated derivative, which forms a covalent linkage to molybdenum via the nitrile group and brings a distinct spectral change of the enzyme. However, only a little 2-hydroxy-FYX-051 was detected, and no other hydroxylation metabolites were observed in an in vivo study (Nakazawa et al., 2006) . Di-and 
